Every 10-Q that Armata Pharmctcl (ARMP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ARMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARMP filings page.
Armata Pharmaceuticals reported a Q2 2026 net income of $74.1 million, driven almost entirely by a $91.0 million noncash gain from remeasuring a related-party Convertible Loan, despite its core operations remaining loss-making. Grant and award revenue was $2.5 million for the quarter, while research and development and general and administrative expenses rose to $7.6 million and $5.2 million, respectively, leading to a Q2 operating loss of $10.3 million and a $19.1 million operating loss for the first half of 2026.
As of June 30 2026, Armata held $24.0 million in cash and cash equivalents and $28.1 million including restricted cash, against $321.1 million in total liabilities, producing a stockholders’ deficit of $231.2 million. The company disclosed that existing cash will not fund operations for the 12 months following issuance of these statements, raising substantial doubt about its ability to continue as a going concern. To bolster liquidity, it drew a new $25.0 million term loan in May 2026 and raised about $2.4 million via its at-the-market equity program during the first half.
Armata continues late-stage development of bacteriophage therapies AP-PA02 and AP-SA02. AP-SA02 for complicated Staphylococcus aureus bacteremia has completed a Phase 1b/2a trial, received QIDP and Fast Track designations from the FDA, and has End-of-Phase 2 feedback supporting advancement to Phase 3, subject to securing additional funding.
Armata Pharmaceuticals’ Q1 2026 report shows a net loss of $115.3M, largely driven by a $101.1M non‑cash loss from revaluing its related‑party Convertible Loan. Grant and award revenue was $0.8M, while research and development expenses reached $6.1M and general and administrative expenses were $3.5M.
Cash and cash equivalents were only $4.8M as of March 31, 2026, and management states this will not fund operations for 12 months, raising “substantial doubt” about the company’s ability to continue as a going concern. Total liabilities were $381.4M, including a fair‑value Convertible Loan of $254.9M and term debt of $88.0M.
The company relies heavily on financing from principal stockholder Innoviva via multiple high‑interest credit agreements and a $100M at‑the‑market equity program. It is preparing a Phase 3 superiority trial of IV phage candidate AP‑SA02 in complicated S. aureus bacteremia, supported by a Qualified Infectious Disease Product designation and up to $26.2M in non‑dilutive Department of Defense funding.
Armata Pharmaceuticals (ARMP) filed its Q3 2025 10-Q reporting a net loss of $26.7M on grant and award revenue of $1.2M. Operating expenses were $8.9M, driven by R&D of $5.8M and G&A of $3.1M. Interest expense was $4.3M, and a change in fair value loss on the Convertible Loan added $14.6M to other expense.
Cash and cash equivalents were $14.8M at September 30, 2025. The company states that existing cash will not fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. Current liabilities were $140.0M, including term debt current of $83.0M and the Convertible Loan at $48.1M measured at fair value. Total liabilities were $185.1M and stockholders’ deficit was $(95.6M).
Financing activity included a $10.0M loan on March 12, 2025 at 14% maturing March 12, 2026, and a $15.0M loan on August 11, 2025 at 14% maturing January 11, 2029, both secured by substantially all assets. Shares outstanding were 36,329,842 as of November 4, 2025.
Armata Pharmaceuticals, Inc. reported a widening operating and net loss in the first half of 2025 as it advances bacteriophage therapeutics. Total assets were $80.8 million versus $86.4 million at year-end 2024, with cash and cash equivalents of $4.3 million and restricted cash of $5.4 million, for combined cash of $9.7 million. The company recorded a six-month net loss of $22.8 million and used $14.8 million of cash in operating activities during the same period.
The balance sheet shows total liabilities of $150.3 million and a stockholders' deficit of $69.5 million, driven by increased current liabilities including a fair-value accounted Convertible Loan of $33.4 million and current term debt of $78.9 million. Management discloses substantial doubt about going concern, stating current cash is insufficient for the next 12 months. Material subsequent financing includes an August 11, 2025 $15.0 million loan from Innoviva at 14% interest; the company also continues to receive MTEC award funding now totaling $26.2 million (term extended to March 31, 2026) to support AP-SA02 development.